Search

Displaying results 2391 - 2400 of 9714 in total
  1. Drug

    Pentoxyverine

    go.drugbank.com/drugs/DB11186
    ApprovedWithdrawn

    Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.

    Mixtures: Pancold AProducts: PENTOXYVERIN AL 19MG/ML, PENTOXYVERIN AL 1.35 MG/ML
  2. Drug

    Benmelstobart

    go.drugbank.com/drugs/DB17473
    Investigational

    APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).

  3. Drug

    DTx-1252

    go.drugbank.com/drugs/DB18086
    Experimental

    DTx-1252 is a siRNA therapeutic under investigation for the treatment of Charcot-Marie-Tooth Disease type 1A (CMTD1A).[L48096]

  4. Drug

    CSIC002

    go.drugbank.com/drugs/DB18584
    Experimental

    CSIC002 is a small-molecule Sema-3A inhibitor. It is being investigated for the treatment of anterior ischemic optic neuropathy.

  5. Drug

    LY-2881835

    go.drugbank.com/drugs/DB15046
    Investigational

    LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).

  6. Drug

    AK106-001616

    go.drugbank.com/drugs/DB16058
    Investigational

    AK106-001616 is under investigation in clinical trial NCT01285752 (A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)).

  7. Drug

    LY-3200882

    go.drugbank.com/drugs/DB16064
    Investigational

    LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).

  8. Drug

    Lisavanbulin

    go.drugbank.com/drugs/DB15224
    Investigational

    Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).

  9. Drug

    Giripladib

    go.drugbank.com/drugs/DB15426
    Investigational

    Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).

  10. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing